60 Degrees Pharmaceuticals (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company to consult on the path forward in developing the tafenoquine regimen of ARAKODA® for a potential indication in treating hospitalized babesiosis patients. The meeting will take place on January 15, 2024.

Reviva Pharmaceuticals (Nasdaq: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, reported financial results for the third quarter ended September 30, 2023 and summarized recent business highlights.“Our brilaroxazine clinical program continues to advance, and we were pleased to recently announce positive topline results for our global Phase 3 RECOVER trial in adults with schizophrenia. The RECOVER trial met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine compared to placebo,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva.

bioAffinity Technologies (Nasdaq: BIAF), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update. "The transformative strategic acquisition of PPLS in September gives us a strong revenue base as we move forward with the rollout of our game-changing CyPath® Lung test. PPLS is forecast to contribute $8.7 million in net revenue over the next 12 months, with additional upside as we work to expand sales of CyPath® Lung regionally and nationally," bioAffinity President and Chief Executive Officer Maria Zannes said.

American Resources Corporation (Nasdaq: AREC), a next generation and socially responsible supplier of rare earth and critical elements, carbon and advanced carbon materials to the new infrastructure and electrification marketplace, announced financial results for the third quarter of 2023. Mark Jensen, Chairman and CEO of American Resources commented, "Throughout the past several months we've continued to execute on our strategic plan of action to monetize our unique platform of assets while continuing to solidify our strategic positioning within the value chain of our addressable markets.